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Abstract
Purpose Defined daily doses (DDD) are used for the
measurement of drug utilisation. The aim of the study was
to analyse whether differences between DDD and pre-
scribed daily doses (PDD) exist for relevant drug classes
such as antihypertensive drugs and, if so, whether they
primarily depend on drug classes or patient-related factors.
Methods Using the data of a large German statutory health
insurance scheme, we analysed continuous prescriptions for
the following antihypertensive drug classes: thiazide diu-
retics, beta-blockers, dihydropyridine calcium channel
blockers (CCBs), angiotensin-converting enzyme inhibitors
(ACEIs) and angiotensin-II receptor blockers (ARBs). We
summed the doses of all dispensed drugs per person during
a defined time frame. We calculated the PDD (= total dose
divided by the number of days) and expressed them as the
PDD:DDD ratio (= amount of DDD per day and person).
Results During the study period, 149,704 patients continu-
ously received an antihypertensive medication. The average
PDD:DDD ratio ranged from 0.84 (beta-blockers) to 1.88
(ARBs) and 2.17 (ACEIs). The average prescribed dosage
of each drug class remained unchanged, even if the patients
had previously received another antihypertensive drug with
another PDD:DDD ratio. For example, if patients were
switched from a beta-blocker to an ACEI, the PDD:DDD
ratio increased, on average, from 0.79 to 2.17. Vice versa,
the ratio decreased for patients with a drug change from an
ACEI to a beta-blocker from 2.06 to 0.75.
Conclusions Even large differences between DDD and
PDD seem to be a matter of drug classes and not primarily
of patient characteristics.
Keywords Drug prescriptions.Drug utilisation review.
Antihypertensive agents.Pharmacoepidemiology.
Databases
Introduction
Defined daily doses (DDD) are used as a standard for the
measurement of drug utilisation and drug exposure in a
population. The WHO [1] defines the DDD as the assumed
average maintenance dose per day for a drug used for its
main indication in adults.
The DDD does not necessarily reflect the recommended
or prescribed daily dose (PDD). Nevertheless, the DDD are
widely used for pharmacoepidemiology studies in a setting
where a consumption of one DDD per day is implied [2],
for example, to compare costs [3, 4], to analyse compli-
ance, to calculate disease prevalences [5, 6]o rt oa s s e s s
the adequacy of a drug supply [7]. Differences between
PDD and DDD have been reported in several studies
focusing on, for example, antiepileptics, antibacterials,
statins or oral hypoglycaemic agents [8–11]. We have
ourselves reported rather large differences between PDD
and DDD for common drugs such as several angiotensin-
converting enzyme inhibitors ( A C E I s )o rc e r t a i na n t i d i a -
betic drugs [12]. However, these discrepancies may be
caused by the severity of diseases or different indications
for a drug.
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1. To confirm our previous results on a broader database
with a focus on a relevant medical indication and not
only one class of drugs.
2. To decide whether differences between PDD and DDD
are due primarily to patient-related or drug-related
factors.
We chose the prescription of antihypertensive drugs,
since hypertension is a major risk factor for many
cardiovascular and related diseases and high blood
pressure has been identified as the leading risk factor
for mortality worldwide [13]. Moreover, multiple drugs
are recommended for the management of hypertension
[14–16] so that the degree of agreement between PDD and
DDD should be relevant for pharmacoepidemiology and
pharmacoeconomics.
Materials and methods
Design
In an observational study, we analysed the prescription data
of patients who received antihypertensive drugs continu-
ously (>3 months) from one or several of the five most
important drug classes: thiazide diuretics (ATC code
C03AA), beta-blockers (C07AB), dihydropyridine calcium
channel blockers (CCBs; C08CA), ACEIs (C09AA), or
angiotensin-II receptor blockers (ARBs; C09CA).
Database
The database for the study consisted of prescription data of
members insured by a single statutory health insurance
(SHI) scheme in the German federal state of Mecklenburg–
Western Pomerania [12]. This SHI scheme is by far the
largest company in this state and insures about one third of
the resident population (about 520,000 out of 1.7 million
people). We analysed the prescription data between January
2006 and September 2007. For each patient record, the
following data were available:
1. The pseudonymised identification number of the
insured person.
2. The central pharmaceutical number. This is an identi-
fication number providing every detail of the package
dispensed, including the ATC classification for the
active substance and the information about the number
of DDD per package.
3. The date of each prescription.
4. Additional prescription data from October 2005 to
December 2007, providing the information as to
whether a drug was also prescribed before or after the
actual study period (January 2006 to September 2007)
Although the prescriptions do not contain information
about the recommended or individual dosage, we tried to
find a satisfying approximation for the actual PDD by
summing the prescriptions of 3-month intervals only for
those patients who also received the analysed drug class
both before and after the 3-month period in question. We
choose a 3-month time frame because, in general, a
patient in Germany with a chronic medication will visit
his or her doctor once every 3 months, i.e. from January
to March, from April to June etc., to receive a new
prescription.
We determined the PDD as the average dispensed daily
dose. To calculate the number of DDD for a patient per
day from the redeemed prescriptions, i.e. the actual PDD
expressed in DDD, we first summed the number of DDD
from all packages of all receipts of each patient per 3-
month period and then divided the summarised prescribed
dose by the number of days over these periods of time.
This approach, i.e. to calculate the PDD solely from the
prescription data, is appropriate since we included only
continuous prescriptions and we checked that every
patient also received the analysed drug class, both before
the study period—as a sort of run-in period to identify
prevalent users—and also after the 3-month period under
study.
Data analysis
According to the aims of our study, we compared PDD and
DDD (expressed as ratios), with a special focus on drug
combinations and drug change, since these events should
help us to better discriminate between patient-related and
drug-related reasons for differences between DDD and
PDD. We defined PDD:DDD ratios, drug combinations and
drug change as follows.
PDD:DDD ratio
We calculated the PDD:DDD ratio, i.e. the PDD denoted in
DDD, prescribed for the patient per day and report the
average ratio for each of the five drug classes.
Drug combinations
Then we compared the PDD:DDD ratio for the different
drug classes between patients who received only one
antihypertensive drug and patients who received a combi-
nation of antihypertensive drugs, i.e. drugs from more than
one of the analysed drug classes. We did not include fixed
combination products in our analysis, because the DDD
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single ingredient products. The DDD for fixed combina-
tions, such as ACEIs or ARBs with diuretics, do not depend
on the dose rate of the single ingredients, but are based on
the average number of dosing intervals per day. For
example, one tablet is the DDD for combinations given
once daily, two tablets is the DDD for combinations given
twice daily etc. [1]. This method of the DDD assignment
would corrupt any attempt to detect discrepancies between
PDD and DDD.
Drug change
In a last step, we compared the PDD:DDD ratios for the
different drug classes for those patients whose antihyper-
tensive medication was changed. For this analysis, we
selected only patients who received an antihypertensive
monotherapy and, again, included only patients who
received the antihypertensive drug continuously both before
and after the drug change. We defined drug change as a
change from one antihypertensive drug class to another
class, e.g. from a beta-blocker to an ACEI. The new drug
could either start in the same 3-month interval as the former
drug ended or in the following 3-month interval (Fig. 1).
Statistics
Given that the aim of the study was to provide an impression
of the magnitude of the differences of prescribed DDD
between the different drug classes, descriptive statistics
provided by the mean, median and interquartile range (IQR)
seemed the most appropriate. No statistical tests were
performed as the high number of patients ensured that even
small differences between the DDD of different drug classes
would be significant, without being clinically relevant.
Results
During the study period, 149,704 patients continuously
received at least one drug from one or more of the five most
important antihypertensive drug classes. For three of the
five drug classes, the PDD:DDD ratio exceeded 1, i.e. the
PDD was higher than the DDD (Table 1); this was most
pronounced for ACEIs with a ratio of 2.17 and ARBs with
a ratio of 1.88, on average. Only for beta-blockers was the
mean daily dosage less than one DDD. The relevant drugs
of each drug class with the respective DDD and PDD:DDD
ratios are shown in Table 2. The different substances within
each group showed some variability. However, while the
PDD:DDD ratios for nearly all beta-blockers did not exceed
1.15, all ratios were considerably higher for the relevant
ACEIs and ARBs.
Interestingly, the upper quartiles of the interquartile
range (IQR) for nearly all PDD:DDD ratios were about
twice as high as the lower quartiles (Table 2). That is to say
that the middle 50% of the patients were treated with a
daily dose between the dose of the lower quartile and two-
fold this dose. For example, the IQR for bisoprolol ranged
from 0.55 to 1.09, resulting in a PDD between 5 and 10 mg
for half of the patients, compared with a DDD of 10 mg. In
the case of ramipril the IQR ranged from 2.17 to 4.38, also
resulting in a dose between 5 and 10 mg for about half of
the patients, this time compared with a DDD of 2.5 mg.
Most of the patients (72%) received only a continuous
medication from one of the investigated antihypertensive
drug classes, 23% had two, and the remainder (5%) were
prescribed drugs from three or more drug classes. If we
compare patients who received only one drug and patients
who received an antihypertensive treatment composed of
more than one drug class, the relation between the PDD:
DDD ratios for the different drug classes remained stable.
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Fig. 1 Two drug change scenarios
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highest PDD:DDD ratio, no matter whether a patient
received only one ARB or additional antihypertensive
drugs. The PDD:DDD ratio for all drug classes rose when
the number of prescribed antihypertensives increased
(Table 3). For example, ARBs were prescribed, on average,
with a PDD:DDD ratio of 1.78 in patients who received one
antihypertensive drug, compared with 2.22 or 2.35 in
Drug class (ATC code) PDD:DDD ratio
a Patients
b
Mean (median) n
Beta-blockers (C07AB) 0.84 (0.73) 79,772
Thiazide diuretics (C03AA) 1.00 (1.09) 8,782
Dihydropyridine calcium channel blockers (C08CA) 1.51 (1.25) 45,750
Angiotensin-II receptor blockers (C09CA) 1.88 (2.13) 17,714
ACE inhibitors (C09AA) 2.17 (2.04) 72,597
Table 1 The prescribed daily
dose (PDD):defined daily dose
(DDD) ratios for different anti-
hypertensive drug classes
aPrescribed DDD per patient per
day
bNumber of patients who received
the drug continuously (>3 months)
Table 2 The DDD and PDD:DDD ratios of the different substances
Drug class (ATC code) DDD (mg) Percentage of patients PDD:DDD ratio
Mean Median; IQR
Beta-blockers (C07AB) 100 0.84
Bisoprolol 10 52 0.75 0.56; 0.55–1.09
Metoprolol 150 33 0.85 0.73; 0.52–1.15
Nebivolol 5 7 1.15 1.10; 1.09–1.11
Talinolol 100 4 1.15 1.10; 0.86–1.37
Atenolol 75 2 0.84 0.73; 0.37–1.15
Other drugs, each with <2% 2 1.05–1.23
Thiazide diuretics (C03AA) 100 1.00
Hydrochlorothiazide 25 100 1.00 1.09; 0.73–1.10
Dihydropyridine calcium channel blockers (C08CA) 100 1.51
Amlodipine 5 37 1.69 1.64; 1.10–2.19
Nitrendipine 20 22 1.27 1.10; 1.00–1.72
Lercanidipine 10 16 1.75 1.83; 1.10–2.19
Nifedipine 30 12 1.03 0.99; 0.67–1.36
Felodipine 5 9 1.58 1.17; 1.10–2.19
Other drugs, each with <2% 4 0.44–1.65
Angiotensin-II receptor blockers (C09CA) 100 1.88
Candesartan 8 26 2.50 2.15; 1.67–3.28
Valsartan 80 21 1.91 2.13; 1.22–2.15
Olmesartan medoxomil 20 20 1.36 1.08; 1.07–2.13
Telmisartan 40 11 1.88 2.14; 1.09–2.15
Irbesartan 150 11 1.76 2.13; 1.08–2.15
Losartan 50 7 1.45 1.09; 1.07–2.00
Eprosartan 600 3 1.10 1.08; 1.07–1.08
ACE inhibitors (C09AA) 100 2.17
Ramipril 2.5 34 3.29 3.13; 2.17–4.38
Enalapril 10 33 1.70 1.47; 1.02–2.20
Lisinopril 10 14 1.64 1.41; 1.09–2.19
Captopril 50 9 1.38 1.10; 0.56–1.97
Quinapril 15 5 1.20 1.10; 0.72–1.47
Other drugs, each with <2% 5 0.93–2.02
IQR = interquartile range (50% of the values lie between the lower and upper limits)
Data in bold are drug classes. The rest are substances
850 Eur J Clin Pharmacol (2011) 67:847–854patients taking three or five distinct antihypertensive drug
classes respectively.
A continuous antihypertensive monotherapy was
changed from one investigated drug class to another in
4,992 patients during the study period. Table 4 shows the
PDD:DDD ratios for the initial and subsequent drug. The
average dose given of a certain drug class, expressed as the
amount of prescribed DDD, was more or less the same
regardless of whether or not doctors had changed the
prescribed drug class during the study period. For example,
569 patients received an ARB after changing the initial
drug class. The average dose for the subsequent ARB
ranged within a small interval of between 1.83 and 2.01
DDD (Table 4, “subsequent drug”, line C09CA, lower
figure), and this interval corresponds to a ratio of 1.88 for
all patients receiving an ARB (Table 1). In sharp contrast,
the dose of the initial drug that the patient received before
the ARB ranged within a large interval of between 0.83 and
2.38, depending on the initial drug class (Table 4, line
C09CA, upper figure).
The same picture arises when we observe the process of
drug change from the perspective of the initial drug. If, for
example, a patient received a CCB as the initial drug, his or
her average dose ranged between 1.43 and 1.65 (Table 4;
“initial drug”, column "C08CA", upper figure). After drug
change, however, the average dose of the subsequent drug
ranged within a large interval from 0.84 to 2.3 (Table 4;
column "C08CA", lower figure). That is to say, the dosage
for a certain drug class prior to (or after) drug change was
more or less the same, no matter what drug or dose the
patient received after (or prior to) the alteration.
Finally, we analysed drug changes on a substance level—
again only for patients with a continuous monotherapy. We
chose switches from bisoprolol to ramipril (242 patients) and
vice versa (174 patients). The substances are the most
commonly prescribed beta-blockers and ACEIs. The PDD:
DDDratiosforbisoprololinpatientsbeforeandafterachange
to ramipril were 0.71 and 0.69, respectively, while the PDD:
DDD ratios for ramipril before and after a change to
bisoprolol were 3.16 and 3.12 respectively (data not shown).
Table 3 The PDD:DDD ratio
a for different antihypertensive drug classes used either as monotherapy or in combination (two to five drugs)
Number of prescribed antihypertensive drug classes
Drug class (ATC code) 1 2 3 4 5
Beta-blockers (C07AB) 0.82 0.88 0.94 1.01 1.10
Thiazide diuretics (C03AA) 1.00 1.00 1.01 1.02 1.09
Dihydropyridine calcium channel blockers (C08CA) 1.46 1.56 1.66 1.76 1.85
Angiotensin-II receptor blockers (C09CA) 1.78 2.01 2.22 2.39 2.35
ACE inhibitors (C09AA) 2.04 2.41 2.91 3.35 3.61
aPrescribed DDD per patient per day
Table 4 Prescribed DDD per patient per day for antihypertensive drug classes used as monotherapy in patients with a drug change
Initial drug
a
Subsequent drug C07AB
(mean)
C03AA
(mean)
C08CA
(mean)
C09CA
(mean)
C09AA
(mean)
Patients
(n)
C07AB (Beta-blockers) – 1.01 1.48 1.83 2.06 1802
– 0.85 0.84 0.81 0.75 1614
C03AA (Thiazide diuretics) 0.84 – 1.65 2.19 2.17 200
0.91 – 0.97 0.98 0.96 238
C08CA (Calcium channel blockers) 0.90 1.08 – 2.14 2.40 1099
1.52 1.70 – 1.52 1.52 1048
C09CA (Angiotensin-II receptor
blockers)
0.83 0.98 1.54 – 2.38 473
1.90 1.84 2.01 – 1.83 569
C09AA (ACE inhibitors) 0.79 1.09 1.43 1.69 – 1418
2.17 2.53 2.3 2.59 – 1523
aThe pairs of figures in the table represent, above, the DDD of the initial drug (i.e. the drug before drug change) and, below,
the DDD of the subsequent drug (i.e. the prescribed drug after drug change)
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Summary of main findings
Depending on the drug class, the PDD for the most relevant
groups of antihypertensive drugs differed from the DDD;
ACEIs were most notable with an average PDD:DDD ratio
of 2.17 recorded, followed by the ARBs with a ratio of
1.88. In patients for whom the doctor changed the drug
class, the PDD:DDD ratio for the new drug was more or
less the same regardless of whether patients had changed to
this drug or had always been prescribed this medication.
Additionally, the PDD:DDD ratio was also observed to be
independent of that of the original drug if they had changed
prescription.
Strengths and limitations of the study
One major advantage of this study is the access to and use
of a reliable and computer-based data set covering all
prescriptions over a sufficient time period. While a single
prescription does not contain a dosage recommendation and
is not suitable for the calculation of PDD, the large data set
in combination with a pseudonymised patient follow-up
enabled us to calculate the PDD solely from prescription
data. Therefore, we selected only those patients who
received continuous medication that started before and
ended after our study period, ensuring medication through-
out the analysed time frame. Cosentino and colleagues [17]
chose a similar study design in their pharmacoepidemio-
logical analysis of drug exposure in a defined population,
but unlike this study we only included patients with
continuous medication. By doing so, we analysed only
prevalent and no incident users. Therefore, we can exclude
the fact that a patient with a drug combination in our dataset
was exposed to a switch.
Additionally, we had no need to restrict the sample size,
which is frequently the case in studies that are based on
information collected directly from patients through surveys
[18].
Although convinced that our study design characteristics
can be expected to ensure a high level of reliability in
calculating the respective PDD our results are predicted on
prescription data and strictly speaking only on those
prescriptions redeemed at pharmacies. Therefore, our only
indicator of treatment adherence is that the prescriptions are
redeemed.
Comparison with the literature and meaning of the study
This is one of the first studies to compare the PDD and DDD
fordrugclassesprescribedforhypertensionasoneofthemost
frequent indications in primary care. The PDDs were higher
than the DDDs for ACEIs, ARBs and dihydropyridine CCBs
—all three groups belong to the most relevant anti-
hypertensivedrugs.Suchdiscrepancieshavealsobeendetected
in studies on other drugs. For example, Muller and colleagues
[9] found a PDD:DDD ratio of 2.97 in amoxicillin–clavulanic
acid for the prescription of antibacterials in a university
hospital. Consequently, if the calculation were based on this
DDD, the number of treatment days in a hospital would be
overestimated. In a Czech university hospital study, differ-
ences in the PDD:DDD ratio in the prescription of anti-
epileptics ranged from 0.5 to 4.0 [8]. The PDD for statins was
up to twice the DDD in a Norwegian study, which compared
statin consumption in different counties [10].
One reason for these discrepancies may be that the drug
classes under study, especially ACEIs, could have been
prescribed for reasons other than hypertension. This
explanation seems at first to be reasonable because ACEIs
represent the drugs of choice not only for the treatment of
hypertension, but also of heart failure and—in the case of
ramipril—cardiovascular prevention, and recommended
dosages are usually higher for these indications [19]. For
cardiovascular prevention, the recommended dose is 10 mg
per day (≙ 4 DDD). This seems to be a rather high dose for
the treatment of hypertension, but it is still permitted as the
maximal dose.
However, according to our analysis of drug change at an
individual patient level, we believe we can exclude this
potential explanation as being the crucial one. Although we
have no information about the indication for the medication
of each individual, it is reasonable to assume that the
indication for a prescription does not change when the
(antihypertensive) drug for the individual patient changes.
Predicting that the PDD:DDD ratio depends on patient-
related factors—irrespective of indication or severity of the
disease or sociodemographic factors like age or gender—
the ratio should not change with a change of the drug. On
the contrary, the ratio should change if not patient-related,
but drug-related factors are relevant. Our results show
clearly that the latter is true. For example, the PDD:DDD
ratio for ACEIs was, on average, above 2 for our entire
cohort, both for patients before a change to beta-blockers
and also for those after change from a beta-blocker. On the
other hand, the PDD:DDD ratio was well below 1 for beta-
blockers, irrespective of whether we looked at all patients
or only at those before a change to an ACEI or those after a
change from an ACEI.
Moreover, we could verify these findings at the level of
individual substances for a switch from the ACEI ramipril
to the beta-blocker bisoprolol and vice versa. Given the
stability of the different PDD:DDD ratios, observed on a
patient level after a drug change, it is hard to conceive that
these differences are mainly caused by patient-related
factors, especially by differences in the indication.
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or the doctor’s dissatisfaction with the efficacy of a drug—
no matter if this would lead to a change of drugs or change
of dose—also seem to be weak for explaining these
consistently observed dosage rates. Again, the above-
mentioned stability of the different PDD:DDD ratios after
drug change is a strong argument against these explan-
ations. Furthermore, differences between the PDD:DDD
ratios remain stable independent of the number of different
drugs the patients received. Assuming the number of
different antihypertensive drugs represents a marker of the
severity of the hypertension [15, 16], our results show that
variations between the PDD:DDD ratios are probably not,
or only to a minimal degree, based on differences in the
severity of a patient’s disease.
Taking this information together, the most logical
explanation for the differences between DDD and PDD
between the drug classes is that this variability represents a
function of the drugs themselves and is not primarily due to
factors associated with patients or doctors. We suppose that
there are different reasons for differences between pre-
scribed doses and the actual DDDs. One reason might be
that the setting and the patient characteristics in clinical
studies, which are often the base for the calculation of
DDDs, are not equivalent to those observed in primary care
settings. Drugs might be highly efficient in clinical studies
because of optimal conditions, whereas general practitioners
may need to prescribe a higher dose than the DDD in reality.
Such “gaps” between pre-market studies and subsequent
clinical practice are well-known and sometimes even lead to
DDD changes over time [20]. For the ACEIs there is a
particular situation insofar as the DDD for all relevant drugs
of this group decreased after market introduction. For
example, the DDD for ramipril was reduced from 5 to
2.5 mg, that for enalapril from 20 to 10 mg respectively
[20, 21]. Without these changes we would have found a far
better correspondence between PDD and DDD. Fears
regarding the adverse effects of this drug class may have
supported a tentative strategy in dose recommendations and
led to DDD alteration after market introduction.
Implications and conclusions
Even for common drug classes such as antihypertensive
drugs, it is not possible to calculate the PDD simply from
the number of prescribed DDD without the information of
the number of patients treated and the time of medication.
Although attractive at first glance, DDD do not represent
the best means of either analysing the appropriateness of an
antihypertensive treatment, or comparing costs between
different drug classes, as a result of the drug class-specific
discrepancy between PDD and DDD. For the same reasons,
it is difficult to assess the degree of drug supply in a
population in terms of patients under antihypertensive
treatment simply by using the number of prescribed DDD.
However, considering these pitfalls adequately, the DDD
system is still useful for pharmacoepidemiology.
It may be an interesting issue for future research to study
in more detail why the discrepancies between DDD and
PDD are rather high in some drug classes and to test our
suggestion that these discrepancies may arise from a
clinical trial setting that does not necessarily reflect real
life or may reflect the manufacturers’ as well as prescribers’
trust and distrust in the effectiveness and possible adverse
effects of new drugs. This could have consequences for the
calculation of the DDD for future drugs.
Acknowledgment We are indebted to the AOK Mecklenburg–
Vorpommern for permission to perform this study with special thanks
to Michael Hewelt for his support.
Conflict of interest The authors declare that they have no conflicts
of interest.
Ethics Ethical approval was not necessary due to the nature of the
data (secondary data analysis of pseudonymised data).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which permits
any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. WHO Collaborating Centre for Drug Statistics Methodology (2009)
Guidelines for ATC classification and DDD assignment 2010. http://
www.whocc.no/filearchive/publications/2010guidelines.pdf.
Accessed 5 January 2011
2. Merlo J, Wessling A, Melander A (1996) A comparison of dose
standard units for drug utilisation studies. Eur J Clin Pharmacol
50:27–30
3. Donohue JM, Fischer MA, Huskamp HA, Weissman JS (2008)
Potential savings from an evidence-based consumer-oriented
public education campaign on prescription drugs. Health Serv
Res 43:1557–1575
4. Schaefer K, Hansen AO, Maerkedahl H, Rehfeld C, Birk HO,
Henriksen LO (2007) Changing GPs’ prescription patterns
through guidelines and feedback. Intervention study. Pharmacoe-
pidemiol Drug Saf 16:695–704
5. Doró P, Benko R, Kosik E, Matuz M, Tóth K, Soós G (2005)
Utilization of oral antihyperglycemic drugs over a 7-year period
(1998–2004) in a Hungarian population and adherence to drug
therapy. Eur J Clin Pharmacol 61:893–897
6. Silwer L, Lundborg CS (2005) Patterns of drug use during a
15 year period: data from a Swedish county, 1988–2002.
Pharmacoepidemiol Drug Saf 14:813–820
7. McManus P, Mant A, Birkett D, Hemming M, Lindner J (1999)
Examining the adequacy of quantities available for subsidized
antidepressant prescriptions in Australia. Pharmacoepidemiol
Drug Saf 8:191–195
Eur J Clin Pharmacol (2011) 67:847–854 8538. Koristkova B, Grundmann M, Brozmanova H (2006) Differences
between prescribed daily doses and defined daily doses of
antiepileptics—therapeutic drug monitoring as a marker of the
quality of the treatment. Int J Clin Pharmacol Ther 44:438–442
9. Muller A, Monnet DL, Talon D, Hénon T, Bertrand X (2006)
Discrepancies between prescribed daily doses and WHO defined
daily doses of antibacterials at a university hospital. Br J Clin
Pharmacol 61:585–591
10. Hartz I, Sakshaug S, Furu K, Engeland A, Eggen AE, Njølstad I,
Skurtveit S (2007) Aspects of statin prescribing in Norwegian
counties with high, average and low statin consumption—an
individual-level prescription database study. BMC Clin Pharmacol
7:14
11. Duarte-Ramos F, Cabrita J (2006) Using a pharmaco-
epidemiological approach to estimate diabetes type 2 prevalence
in Portugal. Pharmacoepidemiol Drug Saf 15:269–274
12. Grimmsmann T, Himmel W (2010) [Relation between Defined
Daily Doses (DDD) and prescribed daily doses: a 3-month
analysis of outpatient data from a statutory health insurance
company] (in German). Gesundheitswesen 72:412–418
13. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK,
He J (2005) Global burden of hypertension: analysis of worldwide
data. Lancet 365:217–223
14. Institute for Quality and Efficiency in Health Care (IQWIG)
(2009) Different antihypertensive drugs as first line therapy in
patients with essential hypertension. Executive Summary of Final
Report A05-09, version 1.0 https://www.iqwig.de/download/A05-
09_Executive_Summary_Antihypertensive_drugs_as_first-
line_therapy.pdf. Accessed 5 January 2011
15. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R,
Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S et al
(2007) 2007 Guidelines for the management of arterial hyperten-
sion: the task force for the management of arterial hypertension of
the European Society of Hypertension (ESH) and of the European
Society of Cardiology (ESC). J Hypertens 25:1105–1187
16. The National Collaborating Centre for Chronic Conditions (NICE)
(2006) Hypertension—management in adults in primary care:
pharmacological update. London. http://www.nice.org.uk/nicemedia/
pdf/HypertensionGuide.pdf. Accessed 5 January 2011
17. Cosentino M, Leoni O, Banfi F, Lecchini S, Frigo G (2000) An
approach for the estimation of drug prescribing using the defined
daily dose methodology and drug dispensation data. Theoretical
considerations and practical applications. Eur J Clin Pharmacol
56:513–517
18. Harder S, Saal K, Blauth E, Beyer M, Gerlach FM (2009)
Appropriateness and surveillance of medication in a cohort of diabetic
patients on polypharmacy. Int J Clin Pharmacol Ther 47:104–110
19. European Society of Cardiology, Heart Failure Association of the
ESC (HFA), European Society of Intensive Care Medicine
(ESICM), Dickstein K, Cohen-Solal A, Filippatos G et al (2008)
ESC guidelines for the diagnosis and treatment of acute and
chronic heart failure 2008: the Task Force for the diagnosis and
treatment of acute and chronic heart failure 2008 of the European
Society of Cardiology. Developed in collaboration with the Heart
Failure Association of the ESC (HFA) and endorsed by the
European Society of Intensive Care Medicine (ESICM). Eur J
Heart Fail 10:933–989
20. Heerdink ER, Urquhart J, Leufkens HG (2002) Changes in
prescribed drug doses after market introduction. Pharmacoepide-
miol Drug Saf 11:447–453
21. WHO Collaborating Centre for Drug Statistics Methodology
(2010) DDD alterations from 1982–2010 (last updated: 9 Jun
2010). http://www.whocc.no/atc_ddd_alterations__cumulative_/
ddd_alterations. Accessed 5 January 2011
854 Eur J Clin Pharmacol (2011) 67:847–854